FY2025 EPS Estimates for TSE:CPH Lowered by Leede Financial

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Research analysts at Leede Financial lowered their FY2025 earnings per share estimates for Cipher Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Leede Financial analyst D. Loe now expects that the company will post earnings per share of $0.87 for the year, down from their previous estimate of $0.93. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals’ FY2026 earnings at $1.00 EPS.

Cipher Pharmaceuticals Stock Performance

Cipher Pharmaceuticals stock opened at C$13.14 on Friday. The company has a debt-to-equity ratio of 41.22, a quick ratio of 2.67 and a current ratio of 2.00. The stock has a fifty day moving average of C$12.91 and a two-hundred day moving average of C$14.52. The company has a market capitalization of C$235.91 million, a price-to-earnings ratio of 14.51 and a beta of 1.20. Cipher Pharmaceuticals has a fifty-two week low of C$7.90 and a fifty-two week high of C$19.69.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.